Comparative Uptake of Tc-99m Sestamibi and Tc-99m Tetrofosmin in Cancer Cells and Tissue Expressing P-Glycoprotein or Multidrug Resistance Associated Protein.
- Author:
Jung Ah CHO
1
;
Jaetae LEE
;
Jung Ah YOO
;
Ji Hyoung SEO
;
Jin Ho BAE
;
Shin Young JEONG
;
Byeong Cheol AHN
;
Sang Gyun SOHN
;
Jeoung Hee HA
;
Kyubo LEE
Author Information
1. Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea. jaetae@knu.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
99mTc-sestamibi;
99mTc-tetrofosmin;
Cancer cell;
Multidrug resistance;
P-glycoprotein;
Multidrug resistance associated protein
- MeSH:
Animals;
Blotting, Western;
Carcinoma, Non-Small-Cell Lung;
Cell Line;
Colorectal Neoplasms;
Cyclosporine;
Drug Resistance;
Drug Resistance, Multiple*;
Humans;
Immunohistochemistry;
Mice;
Mice, Nude;
Multidrug Resistance-Associated Proteins*;
P-Glycoprotein*;
Radioactivity;
Technetium Tc 99m Sestamibi
- From:Korean Journal of Nuclear Medicine
2005;39(1):34-43
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: 99mTc-sestamibi (MIBI) and 99mTc-tetrofosmin have been used as substrates for P-glycoprotein (Pgp) and multidrug resistance associated protein (MRP), which are closely associated with multidrug resistance of the tumors. To understand different handling of radiotracers in cancer cell lines expressing Pgp and MRP, we compared cellular uptakes of 99mTc-MIBI and 99mTc-tetrofosmin. The effects of cyclosporin A (CsA), well-known multidrug resistant reversing agent, on the uptake of both tracers were also compared. MATERIALS AND METHODS: HCT15/CL02 human colorectal cancer cells for Pgp expressing cells, and human non-small cell lung cancer A549 cells for MRP expressing cells, were used for in vitro and in vivo studies. RT-PCR, western blot analysis and immunohistochemistry were used for detection of Pgp and MRP. MDR-reversal effect with CsA was evaluated at different drug concentrations after incubation with MIBI or tetrofosmin. Radioactivities of supernatant and pellet were measured with gamma well counter. Tumoral uptake of the tracers were measured from tumor bearing nude mice treated with or without CsA. RESULTS: RT-PCR, western blot analysis of the cells and immunochemical staining revealed selective expression of Pgp and MRP for HCT15/CL02 and A549 cells, respectively. There were no significant difference in cellular uptakes of both tracers in HCT15/CL02 cells, but MIBI uptake was slightly higher than that of tetrofosmin in A549 cells. Co-incubation with CsA resulted in a increase in cellular uptakes of MIBI and tetrofosmin. Uptake of MIBI or tetrofosmin in HCT15/CL02 cells was increased by 10- and 2.4-fold, and by 7.5 and 6.3-fold in A549 cells, respectively. Percentage increase of MIBI was higher than that of tetrofosmin with CsA for both cells (p< 0.05). In vivo biodistribution study showed that MIBI (114% at 10 min, 257% at 60 min, 396% at 240 min) and tetrofosmin uptake (110% at 10 min, 205% at 60 min, 410% at 240 min) were progressively increased by the time, up to 240 min with CsA. But increases in tumoral uptake were not significantly different between MIBI and tetrofosmin for both tumors. CONCLUSION: MIBI seems to be a better tracer than tetrofosmin for evaluating MDR reversal effect of the modulators in vitro, but these differences were not evident in vivo tumoral uptake. Both MIBI and tetrofosmin seem to be suitable tracers for imaging Pgp- and MRP-mediated drug resistance in tumors.
